<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003335</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU4Y97</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>NCI-G98-1429</secondary_id>
    <secondary_id>CWRU4Y97</secondary_id>
    <nct_id>NCT00003335</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer</brief_title>
  <official_title>A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of
      chemotherapy or radiation therapy and kill more cancer cells.

      PURPOSE: This phase II trial is studying allogeneic umbilical cord blood transplantation to
      see how well it works when given with chemotherapy or radiation therapy in treating patients
      with high-risk hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the rates of hematologic and immune reconstitution in patients with high risk
           hematologic malignancies who are undergoing high dose chemoradiotherapy followed by
           unrelated umbilical cord blood (UCB) transplantation.

        -  Determine the incidence of graft-versus-host-disease in this setting.

        -  Describe the incidence of recurrent disease in these patients post UCB transplant.

        -  Describe the incidence of serious infections and secondary lymphoproliferative diseases
           following transplantation with UCB in these patients.

        -  Determine specifically whether larger recipients can be durably engrafted with unrelated
           UCB, and determine whether nucleated cell or progenitor cell content of the graft is
           predictive of hematological engraftment.

      OUTLINE: Patients may undergo a back-up peripheral blood stem cell collection prior to
      treatment.

      Patients receive 9 fractions of total body irradiation (TBI) on days -9 to -5 followed by
      melphalan IV for three days on days -4 to -2 and antithymocyte globulin IV or
      methylprednisolone IV for three days on days -3 to -1. On day 0, patients receive umbilical
      cord blood infusion. If TBI is not tolerated, busulfan is substituted and administered orally
      every 6 hours for 4 days on days -8 to -5. Cyclosporine and methylprednisolone begin on day
      -2 and continue for 6 months.

      Patients are followed at least monthly for 1 year, then every 6 months for the second year,
      and then annually thereafter.

      PROJECTED ACCRUAL: There will be a maximum of 48 patients accrued into this study over 4
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rates of durable engraftment in patients</measure>
    <time_frame>day 42</time_frame>
    <description>The primary study end point will be hematologic engraftment. Engraftment is defined as achieving ANC larger than or equal to 500 ul/mm3 of donor origin for three consecutive measurements on different days by day +42.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival by clinical and pathological disease assessment</measure>
    <time_frame>at disease progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of recurrent disease in patients post UCB transplant</measure>
    <time_frame>post transplant</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>antithymocyte globulin IV for three days on days -3 to -1</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine begin on day -2 and continue for 6 months.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>melphalan IV for three days on days -4 to -2</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>On day 0, patients receive umbilical cord blood infusion.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>9 fractions of total body irradiation (TBI) on days -9 to -5</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed high risk malignancy including:

               -  Acute nonlymphocytic leukemia (ANLL) after induction failure, or in first
                  complete remission with high risk features including stem cell or biphenotypic
                  classification (acute myeloid leukemia (AML) M0), erythroleukemia (AML M6), acute
                  megakaryocytic leukemia (AML M7), cytogenic markers indicative of poor prognosis,
                  or failure to achieve complete remission after standard induction therapy

               -  Acute lymphocytic leukemia (ALL) or ANLL in second or subsequent remission

               -  Chronic myeloid leukemia (CML) in chronic phase

                    -  CML with accelerated phase or blast crisis are eligible after reinduction
                       chemotherapy converts disease to chronic phase

               -  High risk ALL in first complete remission

               -  Myelodysplastic syndrome with evidence of evolution to acute myeloid leukemia

                    -  Refractory anemia with excess blasts

                    -  Refractory anemia with excess blasts in transformation

               -  Non-Hodgkin's lymphoma (NHL), ANLL, or ALL with recurrent disease after
                  autologous stem cell transplantation

          -  Must also meet all the following conditions:

               -  No HLA-ABC/DR identical related bone marrow or UCB donor

               -  No 5/6 antigen matched related bone marrow or UCB donor

               -  Condition precludes waiting to search and find a donor in the National Marrow
                  Donor Registry

          -  Must have an available serologic matched umbilical cord blood unit in the New York
             Blood Center's Placental Blood Project

          -  No active CNS disease

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 55 at time of umbilical cord blood transplantation

        Performance status:

          -  Zubrod 0-1

          -  Karnofsky 80-100%

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  For patients with ALL or ANLL in remission, CML in chronic phase, or NHL without
             marrow involvement who elect to undergo autologous peripheral blood stem cell
             collection and storage:

               -  WBC at least 3,000/mm^3

               -  Absolute neutrophil count at least 1,000/mm^3

               -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  ALT/AST no greater than 4 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

          -  Creatinine clearance at least 50 mL/min

        Cardiovascular:

          -  Normal cardiac function by echocardiogram or radionuclide scan (shortening fraction or
             ejection fraction at least 80% of normal value for age)

        Pulmonary:

          -  FVC and FEV_1 at least 60% of predicted for age

          -  For adults:

               -  DLCO at least 60% of predicted

        Other:

          -  HIV negative

          -  No active infections at time of autologous stem cell harvest or pretransplant
             cytoreduction

          -  Not pregnant or nursing

          -  Effective contraception required of all fertile patients

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Prior autologous stem cell transplantation allowed

        Chemotherapy:

          -  See Disease Characteristics

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda W. Cooper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lesniewski ML, Haviernik P, Weitzel RP, Kadereit S, Kozik MM, Fanning LR, Yang YC, Hegerfeldt Y, Finney MR, Ratajczak MZ, Greco N, Paul P, Maciejewski J, Laughlin MJ. Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+ T cells. Leukemia. 2008 Dec;22(12):2201-7. doi: 10.1038/leu.2008.234. Epub 2008 Sep 4.</citation>
    <PMID>18769450</PMID>
  </results_reference>
  <results_reference>
    <citation>van Heeckeren WJ, Fanning LR, Meyerson HJ, Fu P, Lazarus HM, Cooper BW, Tse WW, Kindwall-Keller TL, Jaroscak J, Finney MR, Fox RM, Solchaga L, Forster M, Creger RJ, Laughlin MJ. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults. Br J Haematol. 2007 Nov;139(3):464-74.</citation>
    <PMID>17910637</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

